Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inimex Pharmaceuticals, a Canadian biopharmaceutical company, has administered its novel innate defense regulator or IDR IMX942 to human subjects for the first time. The healthy volunteers were enrolled in a Phase I safety study of IMX942 being performed for Inimex in Montreal, Canada with the approval of Health Canada.
Subscribe to our email newsletter
The Phase I healthy volunteer study of IMX942 will provide human safety and pharmacodynamic data, said Inimex.
IMX942 is the first of a new class of drugs known as innate defense regulators, which modulate innate defenses to improve survival, reduce bacterial infections and suppress inflammation.
John North, president and CEO of Inimex Pharmaceuticals, said: “With this transition of IMX942 into clinical development, we are looking forward to demonstrating the safety and biological effects of our IDR drugs in humans. We are excited that we will soon be in a position to test IMX942, the first of this truly innovative new class of drugs, in patients at risk of infection; we expect to launch the first Phase IIa study during 2010 in the US under an investigational new drug application.”
Inimex Pharmaceuticals secured $22 million in series B venture financing in May 2008, providing the resources to enable the company to conduct the first clinical trials of an IDR drug in patients and to evaluate IDRs in a broad range of disease models.